COVID-19 prophylaxis (excluding children) | |
Immunostimulants drugs | |
neutralizing antibody | |
bamlanivimab monotherapy | BLAZE-2 US ... |
casirivimab/imdevimab (Ronapreve) | Cov-2069 ... |
cilgavimab and tixagevimab (Evusheld) | Jurdi PROVENT |
5405 | Ahn, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
5408 | Shen, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
5409 | Ye, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
5410 | Zhang, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
5411 | Zhang, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
5569 | Dai W, 2020 | 2 | 13 | 4 | excluded | not a RCT | high risk of bias |
10178 | Bargay-Lleonart, 2022 | 2 | 1 | 0 | excluded | risk of bias not avaialble |